All articles tagged with #huntingtonsdisease
UniQure's plans to submit its Huntington's disease gene therapy, AMT-130, for FDA approval are now uncertain after the agency indicated it no longer considers existing data sufficient, marking a significant shift from previous communications and causing a 60% drop in the company's premarket shares.
A groundbreaking gene therapy called AMT-130 has shown promising results in slowing the progression of Huntington's disease in a clinical trial, with treated patients experiencing 75% less disease progression and lower neuronal damage markers, potentially offering a new hope for this currently incurable condition.
A new gene therapy for Huntington's disease has shown to slow disease progression by 75%, offering hope for treatment and potentially transforming patient outcomes, though regulatory and cost hurdles remain before it can be widely available on the NHS.
Preliminary results from a small clinical trial show that a gene therapy injected into the brain can slow the progression of Huntington’s disease by 75%, marking a significant breakthrough in treatment for this neurodegenerative condition.
A groundbreaking gene therapy trial in the UK has successfully slowed the progression of Huntington’s disease by 75% over three years, offering new hope for treatment of this incurable genetic disorder.